Aquestive Therapeutics (AQST): CEO sold ~$106K

~$106K

Approx. value · 25K sh @ $4.22

627K

Holds after · shares reported

Traded

Oct 15, 2026

Filed

Oct 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 29, 2026, Aquestive Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has elected Richard J. Daly as a director of the Company, effective October 14, 2026.”
2. Oct 7, 20265% stakeBRATTON DOUGLAS K reported a passive stake (13G) of 0.6%
3. Oct 7, 20265% stakeBass Edward P reported a passive stake (13G) of 7.5%
4. Oct 13, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
5. Oct 15, 2026 · this disclosureInsiderCEO sold ~$106K of AQST shares in the open market

What came next

1. Oct 15, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
2. Nov 3, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. Nov 10, 2026Insider · 1 personInsiders: 2 purchases (~$99K)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Aquestive Therapeutics

For Aquestive Therapeutics, OQRO holds 4 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AQST page.

Other recent filings by Daniel Barber, President and CEO

• SEC Form 4 at Aquestive Therapeutics (AQST)Sep 29, 2025
• SEC Form 4 at Aquestive Therapeutics (AQST)Sep 22, 2025

The full history of Daniel Barber, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Aquestive Therapeutics

• SEC Form 4Nov 12, 2026
• SEC Form 144Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Schedule 13GOct 7, 2026
• SEC Schedule 13GOct 7, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its AQST page.